Eiger BioPharmaceuticals (EIGR) is developing lonafarnib, an oral prenylation inhibitor, to treat Hepatitis D and Progeria. Hepatitis D is typically a superinfection on top of Hepatitis B, leading to a more severe form of the disease. It affects 15-20 million people worldwide, and there is no current therapy approved. In the US, lornafarnib has been granted orphan drug designation for this indication, and it has fast track status in combination with ritonavir. It is in Phase 3 clinical study. Lonafarnib is also being investigated to treat progeria,a very rare autosomal dominant, fatal, premature